Placebo neural systems: Nitric oxide, morphine and the dopamine brain reward and motivation circuitries

Medical Science Monitor

Volumn 11, Issue 5, 2005, Pages

  Fricchione, Gregory ^a,b,d   Stefano, George B ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d Division of General Medicine   (United States)

Author keywords

Limbic; Morphine; Mu3 opiate receptor; Nitric oxide; Placebo; Reward

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; DOPAMINE; MORPHINE; MU OPIATE RECEPTOR; NITRIC OXIDE; PLACEBO;

CONFERENCE PAPER; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; INTERNEURON; LIMBIC CORTEX; MOTIVATION; NERVOUS SYSTEM; NIGRONEOSTRIATAL SYSTEM; PAIN; PARKINSON DISEASE; PERIAQUEDUCTAL GRAY MATTER; PREFRONTAL CORTEX; REGULATORY MECHANISM; REWARD; SIGNAL TRANSDUCTION; STRESS; TEGMENTUM;

ANIMALS; ANXIETY, SEPARATION; BRAIN; DEPRESSION; DOPAMINE; HUMANS; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; MORPHINE; MOTIVATION; NITRIC OXIDE; PAIN; PARKINSON DISEASE; PLACEBO EFFECT; RELAXATION; REWARD; STRESS;

EID: 20344407823     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (92)

1. Guess HA, Kleinman A: The Science of the Placebo: Toward an interdisciplinary research agenda. London: BMJ Books; 2002
2. Stefano GB, Fricchione GL, Slingsby BT, Benson H: The placebo effect and relaxation response: Neural processes and their coupling to constitutive nitric oxide. Brain Research: Brain Research Reviews, 2001; 35: 1-19
3. Ingvar DH: "Memory of the future": an essay on the temporal organization of conscious awareness. Hum Neurobiol, 1985; 4: 127-36
4. Esch T, Fricchione GL, Stefano GB: The therapeutic use of the relaxation response in stress-related diseases. Med Sci Monit, 2003; 9(2): RA23-RA34
5. Stefano GB, Goumon Y, Bilfinger TV et al: Basal nitric oxide limits immune, nervous and cardiovascular excitation: Human endothelia express a mu opiate receptor. Progress in Neurobiology, 2000; 60: 531-44
6. Hrobjartsson A, Gotzsche PC: Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med, 2001; 344: 1594-602
7. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med, 2004; 256: 91-100
8. Hrobjartsson A, Gotzsche PC: Placebo interventions for all clinical conditions. Cochrane Database Syst Rev, 2004; CD003974
9. Spiegel D, Kraemer H, Carlson RW: Is the placebo powerless? N Engl J Med, 2001; 345: 1276-79
10. Slingsby BT, Stefano GB: The active ingredients in the sugar pill: Trust and belief. Placebo, 2001; 2: 33-38
11. Stefano GB, Fricchione GL, Slingsby BT: Is stress stress? Placebo, 2001; 3: 101-10
12. Wager TD, Rilling JK, Smith EE et al: Placebo-induced changes in fMRI in the anticipation and experience of pain. Science, 2004; 303: 1162-67
13. Amanzio M, Benedetti F: Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci, 1999; 19: 484-94
14. Levine JD, Gordon NC, Fields HL: The mechanism of placebo analgesia. Lancet, 1978; 2: 654-57
15. Esch T, Stefano GB: The neurobiology of pleasure, reward processes, addiction and their health implications. Neuroendocrinology Letters, 2004; 25: 235-51
16. Stefano GB: Reply to comment to: Music alters constitutely expressed opiate and cytokine processes in listeners; Med Sci Monit, 2004; 10(6): MS18-MS27.
17. Med Sci Monit, 2004; 10(10): LE19-LE20
18. Petrovic P, Kalso E, Petersson KM, Ingvar M: Placebo and opioid analgesia - imaging a shared neuronal network. Science, 2002; 295: 1737-40
19. Esch T, Guarna M, Bianchi E et al: Commonalities in the central nervous system's involvement with complementary medical therapies: Limbic morphinergic processes. Med Sci Monit, 2004; 10(6): MS6-MS17
20. Price DD, Fields HL: The contribution of desire and expectation to placebo analgesia: Implications for new research strategies. In: Harrington A, editors. The Placebo Effect: An Interdisciplinary Exploration. Cambridge, MA: Harvard Univ Press, 1997; 117-37
21. Polio A, Torre E, Lopiano L et al: Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport, 2002; 13: 1383-86
22. Amanzio M, Polio A, Maggi G, Benedetti F: Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain, 2001;90:205-15
23. Price DD: Endogenous opioid and non-opioid pathways as mediators of placebo analgesia. In: Engel LW, Guess HA, Kleinman A et al: editors. The Science of the Placebo: Toward an Interdisciplinary Research Agenda. London: BMJ Books; 2002; 183-206
24. Shapiro AK, Shapiro E: The Powerful Placebo: From Ancient Priest to Modern Physician. Baltimore, MD: Johns Hopkins Univ Press, 1997
25. Quitkin FM: Placebos, drug effects, and study design: a clinician's guide. Am J Psychiatry, 1999; 156: 829-36
26. Leuchter AF, Cook IA, Witte EA et al: Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry, 2002; 159; 122-29
27. Mayberg HS, Silva JA, Brannan SK et al: The functional neuroanatomy of the placebo effect. Am J Psychiatry, 2002; 159: 728-37
28. de la Fuente-Fernandez R, Ruth TJ, Sossi V et al: Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science, 2001; 293: 1164-66
29. Kirsch I: How Expectancies Shape Experience. Washington, DC: American Psychological Association, 1999
30. Benedetti F, Colloca L, Torre E et al: Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci, 2004; 7: 587-88
31. Benedetti F, Pollo A, Lopiano L et al: Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/ nocebo responses. J Neurosci, 2003; 23: 4315-23
32. de la Fuente-Fernandez R, Stoessl AJ: The placebo effect in Parkinson's disease. Trends Neurosci, 2002; 25: 302-306
33. de la Fuente-Fernandez R, Phillips AG, Zamburlini M et al: Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res, 2002; 136: 359-63
34. de la Fuente-Fernandez R, Schulzer M, Stoessl AJ: Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry, 2004; 56: 67-71
35. de la Fuente-Fernandez R, Stoessl AJ: The biochemical bases for reward. Implications for the placebo effect. Eval Health Prof, 2002; 25: 387-98
36. Fiorillo CD, Tobler PN, Schultz W: Discrete coding of reward probability and uncertainty by dopamine neurons. Science, 2003; 299: 1898-902
37. Schultz W: Predictive reward signal of dopamine neurons. J Neurophysiol, 1998; 80: 1-27
38. Floresco SB, West AR, Ash B et al: Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci, 2003; 6: 968-73
39. Benson H: The relaxation response. New York: William Morrow, 1975
40. Sterling P, Eyer J. Allostasis: A new paradigm to explain arousal pathology. In: Fisher S and Reason J, editors. Handbook of Life, Stress, Cognition, and Health. New York: John Wiley & Sons Ltd, 1998; 629-49
41. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res, 2000; 886: 172-89
42. Epel ES, Blackburn EH, Lin J et al: Accelerated telomere shortening in response to life stress. Prof Natl Acad Sci USA. 2004; 101: 17312-15
43. Kurz DJ, Decary S, Hong Y et al: Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci. 2004; 117: 2417-26
44. Scalera F, Borlak J, Berkmann B et al: Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol. 2004; 24: 1816-22
45. Minamino T, Miyauchi H, Yoshida T et al: Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation, 2002; 105: 1541-44
46. IOM (Institute of Medicine). Health and Behavior. The Interplay of Biological, Behavioral and Societal Influences. Committee on Health and Behavior: Research. Practice and Policy, Board on Neuroscience and Behavioral Health. Washington: National Academy Press, 2001
47. Esch T, Stefano GB, Fricchtone CL, Benson H: Stress-related diseases - a potential role for nitric oxide. Medical Science Monitor, 2002; 8(6): RA103-RA118
48. Wink DA, Mitchell JB: Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radical Biology & Medicine, 1998; 25: 434-56
49. Moncada S, Palmer RM, Higgs EA: Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochemical Pharmacology, 1989; 38: 1709-15
50. Benson H: The relaxation response: therapeutic effect Science, 1997; 278: 1694-95
51. Esch T, Stefano GB: Proinflammation: A common denominator or initiator of different pathophysiological disease processes. Med Sci Monit, 2002; 8(5): HY1-HY9
52. Lembo G, Vecchione C, Izzo R et al: Noradrenergic vascular hyper-responsiveness in human hypertension is dependent on oxygen free radical impairment of nitric oxide activity. Circulation, 2000; 102: 552-57
53. Araki T, Mizutani H, Matsubara M et al: Nitric oxide synthase inhibitors cause motor deficits in mice. Eur Neuropsychopharmacol, 2001; 11: 125-33
54. Zhou X, Espey MG, Chen JX et al: Inhibitor effects of nitric oxide and nitrosative stress on dopamine-beta-hydroxylase. J Biol Chem, 2000; 275: 21241-46
55. Stefano GB, Salzet B, Rialas CM et al: Morphine and anandamide stimulated nitric oxide production inhibits presynaptic dopamine release. Brain Res, 1997; 763: 63-68
56. West, AR, Grace AA: Striatal nitric oxide signaling regulates the neuronal activity of midbrain dopamine neurons in vivo. J Neurophysiol, 2000; 83: 1796-808
57. Carlsson M, Carlsson A: Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci, 1990; 13: 272-76
58. Lazar S, Bush G, Gollub R et al: Functional brain mapping of the relaxation response and meditation. Neuroreport, 2000; 11: 1585
59. West AR, Galloway MP, Grace AA: Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse, 2002; 44: 227-45
60. West AR, Floresco SB, Charara A et al: Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci, 2003; 1003: 53-74
61. Naito A, Kita H: The cortico-nigral projection in the rat: an anterograde tracing study with biotinylated dextran amine. Brain Res, 1994; 637: 317-22
62. Panksepp J: Neuroscience. Feeling the pain of social loss. Science, 2003; 302: 237-39
63. Newman JD, Murpy MR, Harbaugh CR: Naloxone-reversible suppression of isolation call production after morphine injections in squirrel monkeys. Society for Neuroscience Abstracts, 1982; 8: 940
64. Newman JD: The infant cry of primates. An evolutionary perspective. In: Lester BM and Bonkydis CFZ, editors. Infant Crying: Theoretical and Research Perspectives. New York: Plenum Press, 1985; 307-23
65. Fricchione GL, Mendoza A, Stefano GB: Morphine and its psychiatric implications. Adv Neuroimmunol, 1994; 4: 117-32
66. Stefano GB, Scharrer B: Endogenous morphine and related opiates, a new class of chemical messengers. Adv Neuroimmunol, 1994; 4: 57-68
67. Stefano GB, Goumon Y, Casares F et al: Endogenous morphine. Trends in Neurosciences, 2000; 9: 436-42
68. Poeaknapo C, Schmidt J, Brandsch M et al: Endogenous formation of morphine in human cells. Proc Natl Acad Sci USA. 2004; 101: 14091-96
69. Stefano GB, Digenis A, Spector S et al: Opiatelike substances in an invertebrate, a novel opiate receptor on invertebrate and human immunocytes, and a role in immunosuppression. Proc Natl Acad Sci USA. 1993; 90: 11099-103
70. Cadet P, Mantione KJ, Stefano GB: Molecular identification and functional expression of mu3, a novel alternatively spliced variant of the human mu opiate receptor gene. Journal of Immunology, 2003; 170: 5118-23
71. Zhu W, Ma Y, Bell A et al: Presence of morphine in rat amygdala: Evidence for the 3 opiate receptor subtype via nitric oxide release in limbic structures. Med Sci Morit, 2004; 10(12): BR433-BR439
72. Garcia MM, Harlan RE: Stimulus-transcription coupling at the mu opiate receptor. In: Hammer R, editors. The Neurobiology of Opiates. Boca Raton: CRC Press, 1992; 257-99
73. Acquas E, Carboni E, Di Chiara G: Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats. European Journal of Pharmacology, 1991; 193: 133-34
74. Schmidt WJ: Dopamine-glutamate interactions in the basal ganglia. Amino Acids, 1998; 14: 5-10
75. Matsubara K, Fukushima S, Akane A et al: Increased urinary morphine, codeine and tetrahydropapaveroline in parkinsonian patient undergoing L-3,4-dihydroxyphenylalanine therapy: a possible biosynthetic pathway of morphine from L-3,4-dihydroxyphenylalanine in humans. Journal of Pharmacology & Experimental Therapeutics. 1992; 260: 974-78
76. Cadet P, Zhu W, Mantione K et al: Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson's patients. Int J Mol Med, 2003; 12: 485-92
77. Zhu W, Stefano GB: Reticuline exposure to invertebrate Ganglia increases endogenous morphine levels. Neuro Endocrinol Lett, 2004; 25: 323-30
78. Goumon Y, Weeks BS, Cadet P, Stefano GB: Identification of morphine in the adrenal medullary chromaffin PC-12 cell line. Mol Brain Res, 2000; 81: 177-80
79. Davis VE, Walsh MJ: Alcohol, amines and alkaloids: a possible biochemical basis for alcohol addiction. Science, 1970; 167: 1005-7
80. Heinz A, Reimold M, Wrase J et al: Correlation of stable elevations in striatal μ-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry, 2005; 62: 57-64
81. Bianchi E, Alessandrini C, Guarna M, Tagliamonte A: Endogenous codeine and morphine are stored in specific brain neurons. Brain Research, 1993; 627: 210-15
82. Donnerer J, Cardinale G, Coffey J et al: Chemical characterization and regulation of endogenous morphine and codeine in the rat. J Pharmacol Exp Ther, 1987; 242: 583-87
83. Benedetti F, Amanzio M, Baldi S et al: Inducing placebo respiratory depressant responses in humans via opioid receptors. Eur J Neurosci, 1999; 11: 625-31
84. Guarna M, Bianchi E, Bartolini A et al: Endogenous morphine modulates acute thermonociception in mice. J Neurochem, 2002; 80: 271-77
85. Sarnyai Z, Kovacs GL: Role of oxytocin in the neuroadaptation to drugs of abuse. Psychoneuroendocrinology, 1994; 19: 85-117
86. Mintz I: A note on the addictive personality: addiction to placebos. Am J Psychiatry, 1977; 134: 327
87. Stoll AL, Rueter S: Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry, 1999; 156: 2017
88. Kapur S, Mann JJ: Role of the dopaminergic system in depression. Biological Psychiatry, 1992; 32: 1-17
89. Sher L: The role of endogenous opioids in the placebo effect in post-traumatic stress disorder. Forsch Komplementarmed Klass Naturheilkd, 2004; 11: 354-59
90. Harlan RE, Webber DS, Garcia MM: Involvement of nitric oxide in morphine-induced c-Fos expression in the rat striatum. Brain Res Bull, 2001; 54: 207-12
91. Kalivas PW, Duffy P, Dilts R, Abhold R: Enkephalin modulation of A10 dopamine neurons: a role in dopamine sensitization. Annals of the New York Academy of Sciences. 1988; 537: 405-14
92. Kalivas PW, Duffy P, Eberhardt H: Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. Journal of Pharmacology & Experimental Therapeutics. 1990; 253: 858-66